196 related articles for article (PubMed ID: 30803362)
1. Renal Cancer is Not Radioresistant: Slowly but Continuing Shrinkage of the Tumor After Stereotactic Body Radiation Therapy.
Funayama S; Onishi H; Kuriyama K; Komiyama T; Marino K; Araya M; Saito R; Aoki S; Maehata Y; Nonaka H; Tominaga L; Muramatsu J; Nakagomi H; Kamiyama M; Takeda M
Technol Cancer Res Treat; 2019 Jan; 18():1533033818822329. PubMed ID: 30803362
[TBL] [Abstract][Full Text] [Related]
2. Accelerated Hypofractionated Radiotherapy Versus Stereotactic Body Radiotherapy for the Treatment of Stage I Nonsmall Cell Lung Cancer-A Single Institution Experience With Long-Term Follow-Up.
Karasawa K; Hayakawa S; Machitori Y; Shibata Y; Ogawa H; Ito K; Shimizuguchi T; Kawamoto T; Nihei K
Technol Cancer Res Treat; 2018 Jan; 17():1533033818806318. PubMed ID: 30317929
[TBL] [Abstract][Full Text] [Related]
3. Renal cell carcinoma treated with stereotactic radiotherapy with histological change confirmed on autopsy: a case report.
Onishi H; Kawasaki T; Zakoji H; Yoshida T; Komiyama T; Kuriyama K; Araya M; Saito R; Aoki S; Maehata Y; Tominaga L; Marino K; Watanabe I; Oguri M; Araki T; Enomoto N; Takeda M; Katoh R
BMC Res Notes; 2014 Apr; 7():270. PubMed ID: 24767701
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic ablative body radiation therapy for primary kidney cancer: a 3-dimensional conformal technique associated with low rates of early toxicity.
Pham D; Thompson A; Kron T; Foroudi F; Kolsky MS; Devereux T; Lim A; Siva S
Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1061-8. PubMed ID: 25442039
[TBL] [Abstract][Full Text] [Related]
5. Local control rates of metastatic renal cell carcinoma (RCC) to the bone using stereotactic body radiation therapy: Is RCC truly radioresistant?
Amini A; Altoos B; Bourlon MT; Bedrick E; Bhatia S; Kessler ER; Flaig TW; Fisher CM; Kavanagh BD; Lam ET; Karam SD
Pract Radiat Oncol; 2015; 5(6):e589-e596. PubMed ID: 26142027
[TBL] [Abstract][Full Text] [Related]
6. Phase I dose-escalation study of stereotactic body radiotherapy (SBRT) for poor surgical candidates with localized renal cell carcinoma.
Ponsky L; Lo SS; Zhang Y; Schluchter M; Liu Y; Patel R; Abouassaly R; Welford S; Gulani V; Haaga JR; Machtay M; Ellis RJ
Radiother Oncol; 2015 Oct; 117(1):183-7. PubMed ID: 26362723
[TBL] [Abstract][Full Text] [Related]
7. Novel stereotactic body radiation therapy (SBRT)-based partial tumor irradiation targeting hypoxic segment of bulky tumors (SBRT-PATHY): improvement of the radiotherapy outcome by exploiting the bystander and abscopal effects.
Tubin S; Popper HH; Brcic L
Radiat Oncol; 2019 Jan; 14(1):21. PubMed ID: 30696472
[TBL] [Abstract][Full Text] [Related]
8. High-dose-rate stereotactic body radiation therapy for postradiation therapy locally recurrent prostatic carcinoma: Preliminary prostate-specific antigen response, disease-free survival, and toxicity assessment.
Fuller DB; Wurzer J; Shirazi R; Bridge SS; Law J; Mardirossian G
Pract Radiat Oncol; 2015; 5(6):e615-23. PubMed ID: 26059509
[TBL] [Abstract][Full Text] [Related]
9. Intrafraction Motion Management of Renal Cell Carcinoma With Magnetic Resonance Imaging-Guided Stereotactic Body Radiation Therapy.
Prins FM; Stemkens B; Kerkmeijer LGW; Barendrecht MM; de Boer HJ; Vonken EPA; Lagendijk JJW; Tijssen RHN
Pract Radiat Oncol; 2019 Jan; 9(1):e55-e61. PubMed ID: 30261329
[TBL] [Abstract][Full Text] [Related]
10. Impact of 2-staged stereotactic radiosurgery for treatment of brain metastases ≥ 2 cm.
Angelov L; Mohammadi AM; Bennett EE; Abbassy M; Elson P; Chao ST; Montgomery JS; Habboub G; Vogelbaum MA; Suh JH; Murphy ES; Ahluwalia MS; Nagel SJ; Barnett GH
J Neurosurg; 2018 Aug; 129(2):366-382. PubMed ID: 28937324
[TBL] [Abstract][Full Text] [Related]
11. Spine stereotactic body radiotherapy for renal cell cancer spinal metastases: analysis of outcomes and risk of vertebral compression fracture.
Thibault I; Al-Omair A; Masucci GL; Masson-Côté L; Lochray F; Korol R; Cheng L; Xu W; Yee A; Fehlings MG; Bjarnason GA; Sahgal A
J Neurosurg Spine; 2014 Nov; 21(5):711-8. PubMed ID: 25170656
[TBL] [Abstract][Full Text] [Related]
12. The impact of tumor size on outcomes after stereotactic body radiation therapy for medically inoperable early-stage non-small cell lung cancer.
Allibhai Z; Taremi M; Bezjak A; Brade A; Hope AJ; Sun A; Cho BC
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1064-70. PubMed ID: 24210082
[TBL] [Abstract][Full Text] [Related]
13. 4π noncoplanar stereotactic body radiation therapy for head-and-neck cancer: potential to improve tumor control and late toxicity.
Rwigema JC; Nguyen D; Heron DE; Chen AM; Lee P; Wang PC; Vargo JA; Low DA; Huq MS; Tenn S; Steinberg ML; Kupelian P; Sheng K
Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):401-9. PubMed ID: 25482301
[TBL] [Abstract][Full Text] [Related]
14. Radiosurgery or hypofractionated stereotactic radiotherapy for brain metastases from radioresistant primaries (melanoma and renal cancer).
Lesueur P; Lequesne J; Barraux V; Kao W; Geffrelot J; Grellard JM; Habrand JL; Emery E; Marie B; Thariat J; Stefan D
Radiat Oncol; 2018 Jul; 13(1):138. PubMed ID: 30055640
[TBL] [Abstract][Full Text] [Related]
15. Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases.
Wang CJ; Christie A; Lin MH; Jung M; Weix D; Huelsmann L; Kuhn K; Meyer J; Desai N; Kim DWN; Pedrosa I; Margulis V; Cadeddu J; Sagalowsky A; Gahan J; Laine A; Xie XJ; Choy H; Brugarolas J; Timmerman R; Hannan R
Int J Radiat Oncol Biol Phys; 2017 May; 98(1):91-100. PubMed ID: 28587057
[TBL] [Abstract][Full Text] [Related]
16. Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5 cm.
Su TS; Lu HZ; Cheng T; Zhou Y; Huang Y; Gao YC; Tang MY; Jiang HY; Lian ZP; Hou EC; Liang P
BMC Cancer; 2016 Nov; 16(1):834. PubMed ID: 27809890
[TBL] [Abstract][Full Text] [Related]
17. Simulated Online Adaptive Magnetic Resonance-Guided Stereotactic Body Radiation Therapy for the Treatment of Oligometastatic Disease of the Abdomen and Central Thorax: Characterization of Potential Advantages.
Henke L; Kashani R; Yang D; Zhao T; Green O; Olsen L; Rodriguez V; Wooten HO; Li HH; Hu Y; Bradley J; Robinson C; Parikh P; Michalski J; Mutic S; Olsen JR
Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1078-1086. PubMed ID: 27742541
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of stereotactic body radiotherapy (SBRT) treatment of multiple synchronous and recurrent lung nodules.
Owen D; Olivier KR; Mayo CS; Miller RC; Nelson K; Bauer H; Brown PD; Park SS; Ma DJ; Garces YI
Radiat Oncol; 2015 Feb; 10():43. PubMed ID: 25889747
[TBL] [Abstract][Full Text] [Related]
19. Linac-based stereotactic body radiation therapy for unresectable locally advanced pancreatic cancer: risk-adapted dose prescription and image-guided delivery.
Mazzola R; Fersino S; Aiello D; Gregucci F; Tebano U; Corradini S; Di Paola G; Cirillo M; Tondulli L; Ruffo G; Ruggieri R; Alongi F
Strahlenther Onkol; 2018 Sep; 194(9):835-842. PubMed ID: 29696321
[TBL] [Abstract][Full Text] [Related]
20. Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (≥50 cm(3)).
Janowski E; Chen LN; Kim JS; Lei S; Suy S; Collins B; Lynch J; Dritschilo A; Collins S
Radiat Oncol; 2014 Nov; 9():241. PubMed ID: 25398516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
